Koers IRLAB Therapeutics AB (publ) Nasdaq Stockholm
Aandelen
SE0012675361
Farmaceutische producten
Omzet 2023 | 5,68 mln. 525K 488K | Omzet 2024 * | 23,65 mln. 2,19 mln. 2,03 mln. | Marktkapitalisatie | 578 mln. 53,51 mln. 49,71 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -178 mln. -16,47 mln. -15,3 mln. | Nettowinst (verlies) 2024 * | -155 mln. -14,34 mln. -13,32 mln. | EV/omzet 2023 | 48,9 x |
Nettoliquiditeiten 2023 | 111 mln. 10,3 mln. 9,57 mln. | Nettoschuld 2024 * | 25,35 mln. 2,35 mln. 2,18 mln. | EV/omzet 2024 * | 25,5 x |
K/w-verhouding 2023 |
-2,19
x | K/w-verhouding 2024 * |
-3,02
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 57,48% |
Recentste transcriptie over IRLAB Therapeutics AB (publ)
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Clas Sonesson
FOU | Founder | 63 | 01-01-13 |
Chief Executive Officer | 71 | 06-05-17 | |
Nicholas Waters
FOU | Founder | 62 | 01-01-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jan Anders Vedin
BRD | Director/Board Member | 82 | 01-01-16 |
Rein Piir
BRD | Director/Board Member | 66 | 01-01-16 |
Chairman | 66 | 01-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+26,88% | 681 mld. | |
+21,85% | 556 mld. | |
-4,93% | 361 mld. | |
+17,21% | 325 mld. | |
+5,89% | 285 mld. | |
+13,68% | 235 mld. | |
+3,65% | 199 mld. | |
-11,12% | 189 mld. | |
-3,96% | 157 mld. |